Dr Reddy's launches generic version of Imitrex in US

Pharmaceutical major Dr Reddy’s Laboratories today announced that it has launched the authorised generic version of GlaxoSmithKline’s Imitrex (sumatriptan succinate) tablets 25mg, 50mg, and 100mg in the United States. Dr Reddy’s is the first company to launch an authorised generic version of Imitrex tablets in the US market.

In October 2006, the company announced that it had settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets. The specific financial terms and conditions of the settlement have not been disclosed. Imitrex tablets, which are indicated for the treatment of acute migraine attacks in adults, reportedly had US sales of $1.29 billion for the 12-month period ending December 2007.